What Changes in Breast Oncology After ESMO 2026? The Trials, Treatment Shifts, and Unanswered Questions Shaping Clinical Practice

From the first positive overall survival findings with adjuvant ribociclib to a new generation of antibody-drug conjugates challenging conventional chemotherapy, ESMO Congress 2026 has delivered important evidence across nearly every major breast cancer subtype. Yet the meeting’s most consequential message may be that better disease control, greater treatment intensity, and more therapeutic options do not always translate into longer survival.

Held in Madrid from October 23–27, ESMO Congress 2026 brought together long-term results from established phase III trials, pivotal findings from emerging therapies, and exploratory analyses that could influence treatment selection in the coming years.

The most important advances extended across early hormone receptor-positive disease, metastatic HER2-low breast cancer, triple-negative breast cancer (TNBC), and the increasingly complex sequencing of targeted therapies and antibody-drug conjugates (ADCs).

Several findings directly strengthen existing clinical recommendations. Others introduce new treatment candidates but remain dependent on regulatory approval, mature survival data, or confirmation in broader populations.

For practicing oncologists, the central question is no longer simply which trial reported the largest hazard ratio reduction. It is which findings should influence treatment decisions now, which should change future trial design, and which should make clinicians reconsider assumptions about treatment benefit.

Adjuvant CDK4/6 Inhibition: NATALEE Moves From Recurrence Prevention Toward Survival Benefit

One of the most clinically consequential breast cancer presentations at ESMO 2026 was the six-year analysis of the phase III NATALEE trial.

Presented by Dennis Slamon, the study evaluated three years of adjuvant ribociclib combined with a nonsteroidal aromatase inhibitor compared with endocrine therapy alone in patients with stage II–III hormone receptor-positive, HER2-negative early breast cancer.

Earlier analyses established an improvement in invasive disease-free survival (iDFS). The new results provide more mature evidence that reducing recurrence may also translate into prolonged overall survival.

After a median OS follow-up of 66.5 months, the OS hazard ratio was 0.81 (95% CI 0.66–0.99), with a nominal one-sided p-value of 0.019. Six-year OS was 91.9% with ribociclib plus endocrine therapy versus 89.7% with endocrine therapy alone, representing an absolute difference of 2.1 percentage points.

The absolute improvement in six-year iDFS reached 5.3 percentage points, with rates of 83.2% versus 77.9% (HR 0.74). Distant disease-free survival and breast cancer-specific survival also favored ribociclib.

Importantly, patients had been off ribociclib for a median of approximately three years, suggesting persistence of benefit after completion of the planned three-year treatment course. The six-year OS analysis was prespecified but descriptive, and its nominal p-value should not be confused with a newly established multiplicity-controlled confirmatory survival endpoint.

Nevertheless, the findings substantially strengthen the clinical rationale for adjuvant ribociclib in eligible patients at elevated recurrence risk. The practical implications are important. Adjuvant CDK4/6 inhibition is no longer supported only by recurrence prevention; longer-term outcomes are beginning to demonstrate a favorable survival signal.

However, the absolute OS difference remains modest, and treatment selection must continue to consider baseline recurrence risk, toxicity, adherence, monitoring requirements, and the burden of prolonged treatment.

ESMO 2026 therefore reinforces adjuvant ribociclib as an important treatment option without eliminating the need for individualized risk-benefit assessment.

Read About NATALEE Trial on OncoDaily

HER2-Low Breast Cancer: Two New ADCs Intensify Competition

Perhaps the most visible therapeutic shift at ESMO 2026 was the expansion of phase III evidence for HER2-directed ADCs in HER2-low metastatic breast cancer. Trastuzumab deruxtecan (T-DXd) previously established HER2-low disease as a therapeutically actionable category. However, the congress introduced substantial new evidence for additional ADC platforms.

In the phase III HORIZON-Breast06 trial, trastuzumab rezetecan demonstrated a major PFS improvement compared with physician’s choice chemotherapy. Among 551 randomized patients with HER2-low advanced breast cancer, median PFS was 16.4 months versus 6.8 months, respectively, corresponding to an HR of 0.27 (95% CI 0.21–0.34).

Among patients who had not previously received chemotherapy for advanced disease, median PFS was 16.6 versus 6.8 months (HR 0.25). The objective response rate reached 75.5% with trastuzumab rezetecan compared with 41.2% with chemotherapy.

Importantly, benefit was observed across hormone receptor-positive and hormone receptor-negative populations. This broad activity raises the possibility of additional HER2-directed ADC options across biologically distinct HER2-low tumors.

However, grade ≥3 treatment-related adverse events occurred in 84.1% of patients receiving trastuzumab rezetecan, and overall survival remains immature.

Another major result came from APEX-Breast01, evaluating TQB2102, also known as rolditamig deuderuxtecan, a biparatopic HER2-directed ADC.

In patients with hormone receptor-positive, HER2-low recurrent or metastatic disease who had not received chemotherapy for advanced disease, median PFS was 16.4 months with TQB2102 versus 5.5 months with chemotherapy (HR 0.29).

The benefit extended to the overall HER2-low population, while confirmed response rates were approximately doubled. These results establish both agents as important emerging treatment candidates.

However, neither trial demonstrates superiority over trastuzumab deruxtecan or other ADCs. Both studies used chemotherapy comparators, and differences in eligibility, prior treatment, geography, and follow-up make direct cross-trial comparisons unreliable.

What changes after ESMO 2026 is the competitive landscape. HER2-low breast cancer is no longer defined by one successful ADC platform. The future clinical challenge increasingly concerns selection and sequencing among multiple active HER2-directed agents.

Mature survival results, interstitial lung disease risk, hematologic toxicity, access, and efficacy after prior ADC exposure will determine how these new drugs ultimately enter treatment algorithms.

Read About HORIZON-Breast06 Trial on OncoDaily

Hormone Receptor-Positive Metastatic Disease: ADCs Challenge Conventional Chemotherapy

The ADC expansion was not limited to HER2-directed therapy.

In the phase III PANKU-Breast01 trial, izalontamab brengitecan, an investigational bispecific ADC targeting EGFR and HER3, demonstrated substantial activity in previously treated hormone receptor-positive, HER2-negative advanced breast cancer.

Patients had progressed after prior endocrine-based treatment, CDK4/6 inhibition, and chemotherapy. Median PFS was 8.2 months with izalontamab brengitecan versus 4.0 months with physician’s choice chemotherapy, representing a 59% reduction in the hazard of progression or death (HR 0.41; 95% CI 0.33–0.53).

Objective response rates were 40.5% versus 20.2%, while median duration of response was 6.9 versus 4.2 months. Overall survival remains immature.

The significance of this trial extends beyond one investigational drug. It demonstrates that bispecific ADC architectures targeting EGFR and HER3 can achieve substantial clinical activity in heavily pretreated breast cancer, potentially expanding treatment options beyond currently established HER2- and TROP2-directed agents.

Yet the rapid development of these therapies creates a new clinical problem. Patients with endocrine-resistant metastatic breast cancer may now be eligible for several targeted endocrine strategies, PI3K/AKT pathway inhibitors, conventional chemotherapy, and multiple ADCs depending on molecular characteristics and prior exposure.

In that context, treatment sequencing becomes as important as individual drug efficacy. ESMO 2026 reinforces the principle that metastatic breast cancer management increasingly requires reassessment of tumor biology, including ESR1, PIK3CA, AKT1, PTEN, BRCA1/2, and HER2 expression where clinically relevant.

The updated ESMO metastatic breast cancer guidelines published earlier in 2026 already reflected this shift. The congress added new evidence likely to intensify the need for more individualized sequencing strategies.

Triple-Negative Breast Cancer: More Evidence for Earlier and More Durable ADC Benefit

Triple-negative breast cancer remains a major focus of ADC development, particularly as TROP2-directed therapies move into earlier metastatic treatment lines.

At ESMO 2026, the final OS analysis of OptiTROP-Breast01 provided important long-term evidence for sacituzumab tirumotecan (sac-TMT) in previously treated metastatic TNBC. With 29.4 months of median follow-up, median OS remained 14.7 months with sac-TMT versus 9.9 months with chemotherapy, corresponding to an HR of 0.60 (95% CI 0.45–0.80).

At 30 months, estimated survival was 26.8% versus 13.2%, supporting durability of the benefit. Importantly, 27.8% of patients in the chemotherapy arm received subsequent ADC treatment. After statistical adjustment for later ADC exposure, the OS HR remained favorable at 0.55.

The final analysis was descriptive because statistical significance had already been established at the prespecified interim analysis. The findings therefore strengthen an established survival advantage rather than representing a new independent confirmatory test.

Meanwhile, new data from TROPION-Breast02 explored the activity of datopotamab deruxtecan in first-line metastatic TNBC among patients for whom immunotherapy was not an option. In the exploratory population with baseline brain metastases, median systemic PFS was 7.7 months with datopotamab deruxtecan versus 3.5 months with chemotherapy (HR 0.37).

Median CNS progression-free survival was 9.5 versus 2.6 months (HR 0.27), while confirmed intracranial response rates favored the ADC. These results are clinically encouraging because CNS disease remains a major treatment challenge in TNBC.

However, the analysis involved relatively few patients, and the findings should not be used to replace established local CNS treatment strategies without further validation.

Together, OptiTROP-Breast01 and TROPION-Breast02 reinforce the growing importance of ADCs in TNBC, while raising unresolved questions about how to sequence multiple TROP2-directed agents and whether activity can be preserved after exposure to another ADC with a related cytotoxic payload.

Read About OptiTROP-Breast01 Trial on OncoDaily

HER2-Positive Disease: CNS Activity and Patient-Centered Outcomes Gain Importance

In HER2-positive breast cancer, ESMO 2026 contributed additional evidence to treatment strategies that were already changing clinical practice.

The phase III DESTINY-Breast09 trial had previously demonstrated superior first-line PFS with trastuzumab deruxtecan plus pertuzumab compared with taxane, trastuzumab, and pertuzumab. An exploratory analysis presented at ESMO 2026 focused on patients with baseline brain metastases.

Among 61 evaluable patients, median PFS was 36.5 months with trastuzumab deruxtecan plus pertuzumab versus 11.1 months with the comparator regimen. Median CNS-PFS was not estimable versus 9.7 months, with an HR of 0.26 (95% CI 0.11–0.57). Confirmed intracranial response rates were 51.6% versus 26.7%.

These results suggest meaningful CNS activity with upfront T-DXd-based treatment, although the exploratory sample size limits definitive conclusions.

In early HER2-positive breast cancer, DESTINY-Breast05 provided additional patient-reported outcome data supporting the previously demonstrated efficacy advantage of T-DXd over T-DM1 in high-risk residual invasive disease after neoadjuvant treatment.

The new analysis suggested broadly maintained global quality of life with both treatments, without clear differences in several major patient-reported domains. These results add a patient-centered dimension to earlier efficacy findings, which showed three-year invasive disease-free survival of 92.4% versus 83.7%.

Notably, this treatment strategy was already evolving before ESMO 2026. T-DXd received US approval for this post-neoadjuvant indication in May 2026 and European Union approval on October 27, 2026.

The implication is not that the congress independently established a new indication, but that additional evidence continues to refine how an increasingly effective treatment can be delivered while preserving quality of life.

Negative and Mixed Trials: Not Every PFS Gain Changes Practice

Some of the most instructive results at ESMO 2026 were studies in which improvements in disease control did not translate into statistically significant overall survival benefits.

The phase III KEYNOTE-B49 trial evaluated pembrolizumab plus chemotherapy in PD-L1-positive hormone receptor-positive, HER2-negative advanced breast cancer after progression on endocrine therapy. Median PFS was 6.7 versus 6.0 months (HR 0.74), meeting the prespecified PFS significance criterion.

However, final median OS was 21.0 versus 22.2 months (HR 1.04; p=0.6185), without a survival advantage. The modest median PFS difference, increased treatment burden, and negative OS result do not support routine expansion of pembrolizumab plus chemotherapy into this population based on these findings.

Similarly, the final OS analysis of postMONARCH showed numerically longer median survival with abemaciclib plus fulvestrant after prior CDK4/6 inhibition: 32.1 versus 24.6 months.

However, the OS HR of 0.80 (95% CI 0.60–1.06; p=0.11) did not cross the prespecified statistical significance boundary.

The study therefore continues to support an option for additional disease control in selected patients without demonstrating a confirmed survival extension. The FINER trial also failed to demonstrate a significant OS benefit with ipatasertib plus fulvestrant despite earlier PFS improvement.

These findings have a broader implication: extending PFS remains clinically relevant, especially when associated with improved symptoms or delayed chemotherapy. However, small PFS gains should be interpreted alongside toxicity, quality of life, subsequent treatment, and the strength of the evidence for prolonged survival.

Read About KEYNOTE-B49 Trial on OncoDaily

Early Breast Cancer: Intensification Is Not Always the Answer

Another important message came from the phase II TALENT study investigating neoadjuvant T-DXd in hormone receptor-positive, HER2-low early breast cancer.

Despite substantial radiological tumor responses, pathological complete response (pCR) rates remained low. pCR was observed in approximately 7% of patients receiving T-DXd alone, 3% receiving T-DXd plus anastrozole, and 9% receiving T-DXd followed by chemotherapy.

Although pCR is an imperfect surrogate endpoint in hormone receptor-positive disease, these results do not establish T-DXd as an alternative to standard neoadjuvant strategies in HER2-low early breast cancer.

The findings illustrate that impressive ADC activity in metastatic disease does not automatically translate into comparable pathological responses or proven curative benefit. Long-term endocrine therapy also received renewed attention.

In the final analysis of NSABP B-42, extended adjuvant letrozole improved disease-free survival and reduced distant recurrence after previous endocrine treatment, but did not significantly improve overall survival after approximately 16 years of follow-up.

These findings support individualized decisions regarding endocrine therapy duration rather than universal treatment extension. Together, the early-stage results highlight the importance of selecting patients according to absolute recurrence risk and expected benefit, particularly when treatment is administered with curative intent.

Read About TALENT Trial on OncoDaily

What Should Oncologists Actually Change After ESMO 2026?

The congress does not justify replacing established treatment algorithms with every newly presented regimen. Instead, the findings suggest several increasingly important principles.

In early hormone receptor-positive disease, the NATALEE survival findings strengthen the rationale for adjuvant ribociclib among eligible patients, while reinforcing the importance of carefully weighing absolute benefit against prolonged treatment exposure.

In HER2-low metastatic disease, strong results from HORIZON-Breast06 and APEX-Breast01 expand the evidence supporting ADC development, but neither study provides a direct comparison with existing ADC standards.

In hormone receptor-positive metastatic disease, PANKU-Breast01 highlights an important emerging bispecific ADC strategy, while postMONARCH and FINER demonstrate why biomarker selection and evidence maturity remain critical.

In TNBC, sustained survival benefit with sacituzumab tirumotecan and promising intracranial activity with datopotamab deruxtecan strengthen the ADC evidence base without resolving optimal sequencing.

And in HER2-positive disease, new CNS and quality-of-life analyses support increasingly individualized decisions regarding the timing, intensity, and tolerability of ADC-based treatment.

Across subtypes, the interpretation of treatment benefit is becoming more complex. The choice between endocrine therapy, targeted agents, chemotherapy, immunotherapy, and ADCs now depends increasingly on molecular characteristics, previous treatment exposure, CNS involvement, regulatory availability, and the expected balance between benefit and harm.

OncoDaily Takeaway

ESMO Congress 2026 marks a further transition in breast oncology from demonstrating that new treatments are active to determining how they should be positioned within increasingly crowded treatment pathways.

The six-year NATALEE findings stand among the most clinically consequential developments, strengthening the evidence that adjuvant CDK4/6 inhibition can deliver benefits beyond recurrence prevention. However, the absolute survival improvement remains modest, reinforcing the need for thoughtful patient selection.

The ADC revolution has entered a new phase. HORIZON-Breast06, APEX-Breast01, PANKU-Breast01, and OptiTROP-Breast01 collectively demonstrate that multiple antibody-drug conjugate platforms can deliver substantial clinical benefit across HER2-low, hormone receptor-positive, and triple-negative breast cancer. Yet the growing number of active agents is creating new questions about sequence, cross-resistance, toxicity, and whether benefits persist after prior ADC exposure.

Equally important were the trials that did not establish an overall survival advantage. KEYNOTE-B49, postMONARCH, and FINER illustrate why a favorable PFS result, particularly when modest or accompanied by additional toxicity, should not automatically be interpreted as a practice-changing survival benefit.

In early breast cancer, TALENT demonstrates that the success of ADCs in metastatic disease cannot simply be transferred into curative-intent treatment. Meanwhile, long-term endocrine therapy data reinforce the importance of matching treatment duration and intensity to individual recurrence risk.

The most important change after ESMO 2026 may therefore be conceptual. Modern breast oncology is moving beyond broad molecular subtype classification toward treatment strategies shaped by current tumor biology, resistance mechanisms, previous exposures, and patient-specific priorities.

The next era of breast oncology will not be defined only by more effective drugs. It will be defined by using them earlier when justified, selecting them more precisely, sequencing them more intelligently, and demanding mature evidence that their benefits matter to patients.

Source

Selected presentations from ESMO Congress 2026, Madrid, Spain, October 23–27, 2026:

1. Slamon DJ, et al. NATALEE six-year overall survival and efficacy analysis. LBA25.
2. Fan Y, et al. HORIZON-Breast06: Trastuzumab rezetecan in HER2-low advanced breast cancer. LBA13. JAMA, 2026.
3. Wang S, et al. APEX-Breast01: TQB2102 versus chemotherapy. LBA27.
4. Lan B, et al. PANKU-Breast01: Izalontamab brengitecan versus chemotherapy. LBA50.
5. Li M, et al. OptiTROP-Breast01 final overall survival analysis. Abstract 4639RO.
6. Dent RA, et al. TROPION-Breast02 exploratory brain metastasis analysis. LBA96.
7. Saura Manich C, et al. DESTINY-Breast09 CNS analysis. LBA49.
8. Rugo HS, et al. KEYNOTE-B49 phase III final results. LBA51.
9. Kalinsky K, et al. postMONARCH final overall survival results.
10. Hurvitz SA, et al. TALENT final neoadjuvant results. LBA23.
11. Mamounas EP, et al. NSABP B-42 final analysis. LBA24.
12. Redfern A, et al. FINER overall survival analysis. LBA14.